Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Definiens Closes €10 Million Round to Grow its Clinical Digital Pathology Business

Published: Tuesday, October 02, 2012
Last Updated: Tuesday, October 02, 2012
Bookmark and Share
The financing was led by new investor Gilde Healthcare Partners, a transatlantic investment firm with €450 million under management, focusing on the private healthcare sector.

Existing investors, including TVM, Cipio and Definiens’ management also participated in the financing round.

Definiens will primarily use the funding for commercial expansion of its current business and to develop and commercialize innovative products for Clinical Digital Pathology. The company’s solutions are currently being used for research and development by all major pharmaceutical companies as well as an increasing number of diagnostic companies in tissue based diagnostic biomarker development.

Dr Janke Dittmer, partner at Gilde Healthcare Partners, has joined the Company’s Supervisory Board.

“This new round of funding allows Definiens’ to grow its Clinical Digital Pathology business,” said Thomas Heydler, CEO of Definiens. “Gilde Healthcare Partners joins our team of committed investors. With their financial support and partnership, we will build on the success of our existing business and increase our presence in the clinical routine use of Digital Pathology.”

“Digital Pathology combined with the right image analysis tools has the potential to transform cancer diagnosis. As the market leader in image analysis for Digital Pathology Definiens is well positioned to unlock the full potential of tissue based diagnostics and drive the clinical adoption of quantitative Digital Pathology.” said Janke Dittmer. “We led this investment round because we believe that Definiens has a set of market leading products, a strong patent portfolio and unique capabilities to turn new concepts into clinically relevant products which will benefit people suffering from cancer around the world.”

Definiens’ proprietary Cognition Network Technology® enables best in class analysis of Digital Pathology images, but can also be used on other types of images. It is the brainchild of Definiens' founder, CTO and Nobel Laureate Prof Dr Gerd Binnig. Its context based segmentation approach leads to unsurpassed accuracy in detecting structures of interest and is robust with regard to variations in the tissue and the scanner used.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics
Big data approach bridges the gap between genomics and personalized medicine.
Saturday, June 28, 2014
Definiens Expands Management Team to Develop the Clinical Market
Company announces appointment of Pablo Jordan and Rebecca Berghorn.
Tuesday, October 29, 2013
Definiens Appoints Chief Marketing Officer, Merrilyn Datta, Ph.D.
Dr. Datta brings a wealth of experience in marketing and her expertise will be critical as Definiens expands its leadership in the life sciences and tissue diagnostics industries.
Tuesday, April 09, 2013
Definiens Establishes Advisory Board
Renowned industry experts to advise Definiens on clinical digital pathology market.
Thursday, March 28, 2013
Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Definiens AG announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman.
Thursday, November 15, 2012
Scientific News
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
Genetic Approach May Lead to New Treatments for Digestive Diseases
Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
World-First Blood Test For Parkinson's
La Trobe University researchers have developed a world-first diagnostic blood test which could change the lives of people with Parkinson's disease.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Hepatitis C Virus Testing Guidelines Miss Too Many Cases
Urban emergency departments a good place to enact universal screening for adults.
NIH Sequences Genome of a Fungus
Researchers at the Institute have sequenced genome of human, mouse and rat Pneumocystis that cause life-threatening Pneumonia in immunosuppressed hosts.
Antibiotic Resistance Mechanism Continues to Spread
A recently discovered genetic mechanism allowing bacteria to develop and transfer resistance to colistin, one of the last-resort antibiotics, has been present in many countries across the world for more than a decade, according to late-breaking data presented at ECCMID.
Promising New Method Inhibits TB-Causing Bacteria
Researchers at UQ and UC San Francisco have found a new way to inhibit the growth of the bacterium that causes tuberculosis.
Liquid Biopsy for NSCLC
'Liquid biopsy' blood test accurately detects key genetic mutations in most common form of lung cancer, study finds.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!